ID   CP4AE_RAT               Reviewed;         507 AA.
AC   P20817;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   24-JUL-2024, entry version 164.
DE   RecName: Full=Cytochrome P450 4A14;
DE   AltName: Full=CYPIVA14;
DE   AltName: Full=Cytochrome P450-LA-omega 3;
DE   AltName: Full=Lauric acid omega-hydroxylase;
DE   AltName: Full=Long-chain fatty acid omega-monooxygenase;
DE            EC=1.14.14.80 {ECO:0000250|UniProtKB:Q02928};
DE   Flags: Precursor;
GN   Name=Cyp4a14 {ECO:0000312|RGD:631356};
GN   Synonyms=Cyp4a-3, Cyp4a3 {ECO:0000303|PubMed:10869363};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=2766933; DOI=10.1089/dna.1.1989.8.517;
RA   Kimura S., Hardwick J.P., Kozak C.A., Gonzalez F.J.;
RT   "The rat clofibrate-inducible CYP4A subfamily. II. cDNA sequence of IVA3,
RT   mapping of the Cyp4a locus to mouse chromosome 4, and coordinate and
RT   tissue-specific regulation of the CYP4A genes.";
RL   DNA 8:517-525(1989).
RN   [2]
RP   PROTEIN SEQUENCE OF 5-19.
RX   PubMed=3365247; DOI=10.1016/s0006-291x(88)80092-5;
RA   Imaoka S., Shimojo N., Funae Y.;
RT   "Induction of renal cytochrome P-450 in hepatic microsomes of diabetic
RT   rats.";
RL   Biochem. Biophys. Res. Commun. 152:680-687(1988).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-63; LYS-91; THR-92;
RP   ALA-113; 114-SER--ILE-116 AND PHE-119, AND PATHWAY.
RX   PubMed=10869363; DOI=10.1074/jbc.m004841200;
RA   Hoch U., Falck J.R., de Montellano P.R.;
RT   "Molecular basis for the omega-regiospecificity of the CYP4A2 and CYP4A3
RT   fatty acid hydroxylases.";
RL   J. Biol. Chem. 275:26952-26958(2000).
RN   [4]
RP   COVALENT HEME ATTACHMENT.
RX   PubMed=11139583; DOI=10.1074/jbc.m009969200;
RA   Hoch U., Ortiz de Montellano P.R.;
RT   "Covalently linked heme in cytochrome P4504A fatty acid hydroxylases.";
RL   J. Biol. Chem. 276:11339-11346(2001).
RN   [5]
RP   COVALENT HEME ATTACHMENT, AND MUTAGENESIS OF GLU-318.
RX   PubMed=11821421; DOI=10.1074/jbc.m112155200;
RA   LeBrun L.A., Hoch U., Ortiz de Montellano P.R.;
RT   "Autocatalytic mechanism and consequences of covalent heme attachment in
RT   the cytochrome P4504A family.";
RL   J. Biol. Chem. 277:12755-12761(2002).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-437, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: A cytochrome P450 monooxygenase that catalyzes omega and
CC       omega-1 hydroxylation of saturated fatty acids. Exhibits preferential
CC       omega versus omega-1 regioselectivity and (R) versus (S)
CC       stereoselectivity for hydroxylation of dodecanoic (lauric) acid.
CC       Mechanistically, uses molecular oxygen inserting one oxygen atom into a
CC       substrate, and reducing the second into a water molecule, with two
CC       electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-
CC       ferrihemoprotein reductase). {ECO:0000269|PubMed:10869363}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an omega-methyl-long-chain fatty acid + O2 + reduced [NADPH--
CC         hemoprotein reductase] = an omega-hydroxy-long-chain fatty acid +
CC         H(+) + H2O + oxidized [NADPH--hemoprotein reductase];
CC         Xref=Rhea:RHEA:56748, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:140991,
CC         ChEBI:CHEBI:140992; EC=1.14.14.80;
CC         Evidence={ECO:0000269|PubMed:10869363};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dodecanoate + O2 + reduced [NADPH--hemoprotein reductase] =
CC         (11R)-hydroxydodecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein
CC         reductase]; Xref=Rhea:RHEA:41724, Rhea:RHEA-COMP:11964, Rhea:RHEA-
CC         COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:18262, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210,
CC         ChEBI:CHEBI:78423; Evidence={ECO:0000269|PubMed:10869363};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41725;
CC         Evidence={ECO:0000305|PubMed:10869363};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dodecanoate + O2 + reduced [NADPH--hemoprotein reductase] =
CC         12-hydroxydodecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein
CC         reductase]; Xref=Rhea:RHEA:38947, Rhea:RHEA-COMP:11964, Rhea:RHEA-
CC         COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:18262, ChEBI:CHEBI:36204, ChEBI:CHEBI:57618,
CC         ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:10869363};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38948;
CC         Evidence={ECO:0000305|PubMed:10869363};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O2 + reduced [NADPH--hemoprotein reductase] + tetradecanoate =
CC         14-hydroxytetradecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein
CC         reductase]; Xref=Rhea:RHEA:40203, Rhea:RHEA-COMP:11964, Rhea:RHEA-
CC         COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:30807, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210,
CC         ChEBI:CHEBI:77033; Evidence={ECO:0000269|PubMed:10869363};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40204;
CC         Evidence={ECO:0000305|PubMed:10869363};
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000269|PubMed:11139583, ECO:0000269|PubMed:11821421};
CC   -!- PATHWAY: Lipid metabolism; fatty acid metabolism.
CC       {ECO:0000305|PubMed:10869363}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein. Microsome membrane; Peripheral membrane protein.
CC   -!- INDUCTION: By clofibrate.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M33936; AAA41458.1; -; mRNA.
DR   PIR; A32966; A32966.
DR   PIR; PC4351; PC4351.
DR   RefSeq; NP_786936.1; NM_175760.2.
DR   AlphaFoldDB; P20817; -.
DR   SMR; P20817; -.
DR   SwissLipids; SLP:000000744; -.
DR   iPTMnet; P20817; -.
DR   PhosphoSitePlus; P20817; -.
DR   GeneID; 298423; -.
DR   KEGG; rno:298423; -.
DR   UCSC; RGD:631356; rat.
DR   AGR; RGD:631356; -.
DR   CTD; 298423; -.
DR   RGD; 631356; Cyp4a3.
DR   InParanoid; P20817; -.
DR   OrthoDB; 1611592at2759; -.
DR   PhylomeDB; P20817; -.
DR   BRENDA; 1.14.14.80; 5301.
DR   Reactome; R-RNO-211935; Fatty acids.
DR   Reactome; R-RNO-211958; Miscellaneous substrates.
DR   Reactome; R-RNO-211979; Eicosanoids.
DR   Reactome; R-RNO-2142691; Synthesis of Leukotrienes (LT) and Eoxins (EX).
DR   UniPathway; UPA00199; -.
DR   PRO; PR:P20817; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IBA:GO_Central.
DR   GO; GO:0018685; F:alkane 1-monooxygenase activity; IMP:RGD.
DR   GO; GO:0008391; F:arachidonic acid monooxygenase activity; IMP:RGD.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0102033; F:long-chain fatty acid omega-hydroxylase activity; IEA:UniProtKB-EC.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; IMP:RGD.
DR   GO; GO:0046456; P:icosanoid biosynthetic process; IMP:RGD.
DR   GO; GO:0001822; P:kidney development; IEP:RGD.
DR   GO; GO:0048252; P:lauric acid metabolic process; IDA:RGD.
DR   GO; GO:0043651; P:linoleic acid metabolic process; IDA:RGD.
DR   GO; GO:1904681; P:response to 3-methylcholanthrene; IEP:RGD.
DR   CDD; cd20678; CYP4B-like; 1.
DR   Gene3D; 1.10.630.10; Cytochrome P450; 1.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   InterPro; IPR036396; Cyt_P450_sf.
DR   InterPro; IPR050196; Cytochrome_P450_Monoox.
DR   PANTHER; PTHR24291:SF47; CYTOCHROME P450 4A14-RELATED; 1.
DR   PANTHER; PTHR24291; CYTOCHROME P450 FAMILY 4; 1.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; Cytochrome P450; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Endoplasmic reticulum; Heme; Iron; Membrane;
KW   Metal-binding; Microsome; Monooxygenase; NADP; Oxidoreductase;
KW   Phosphoprotein; Reference proteome.
FT   PROPEP          1..4
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000269|PubMed:3365247"
FT                   /id="PRO_0000003569"
FT   CHAIN           5..507
FT                   /note="Cytochrome P450 4A14"
FT                   /id="PRO_0000003570"
FT   BINDING         318
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /note="covalent"
FT                   /evidence="ECO:0000269|PubMed:11139583,
FT                   ECO:0000269|PubMed:11821421"
FT   BINDING         454
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000269|PubMed:11139583,
FT                   ECO:0000269|PubMed:11821421"
FT   MOD_RES         437
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MUTAGEN         63
FT                   /note="D->N: Has no significant effect on the catalytic
FT                   activity toward lauric and myristic acids."
FT                   /evidence="ECO:0000269|PubMed:10869363"
FT   MUTAGEN         91
FT                   /note="K->T: Impairs substrate binding."
FT                   /evidence="ECO:0000269|PubMed:10869363"
FT   MUTAGEN         92
FT                   /note="T->A: Has no significant effect on the catalytic
FT                   activity toward lauric and myristic acids."
FT   MUTAGEN         113
FT                   /note="A->P: 70-fold increase of the binding constant for
FT                   lauric acid associated with higher catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:10869363"
FT   MUTAGEN         114..116
FT                   /note="Missing: Higher kcat for hydroxylation of lauric
FT                   acid. 2-fold increase of omega/(omega-1) hydroxylation
FT                   ratio for lauric and myristic acids; when associated with
FT                   S-119."
FT                   /evidence="ECO:0000269|PubMed:10869363"
FT   MUTAGEN         119
FT                   /note="F->S: 7-fold increase of the binding constant for
FT                   lauric acid associated with higher catalytic activity. 2-
FT                   fold increase of omega/omega-1 hydroxylation ratio for
FT                   lauric and myristic acids; when associated with
FT                   S114_I116del."
FT                   /evidence="ECO:0000269|PubMed:10869363"
FT   MUTAGEN         318
FT                   /note="E->A: Loss of covalent heme binding."
FT                   /evidence="ECO:0000269|PubMed:11821421"
FT   MUTAGEN         318
FT                   /note="E->D: Significant reduction in covalent heme
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:11821421"
FT   MUTAGEN         318
FT                   /note="E->Q: Significant reduction in covalent heme
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:11821421"
SQ   SEQUENCE   507 AA;  58232 MW;  1A972C6F967BF1AB CRC64;
     MGFSVFTPTR SLDGVSGFFQ GAFLLSLFLV LFKAVQFYLR RQWLLKALEK FPSTPSHWLW
     GHDLKDREFQ QVLTWVEKFP GACLQWLSGS KTRVLLYDPD YVKVVLGRSD PKASGIYQFL
     APWIGYGLLL LNGKKWFQHR RMLTPAFHYG ILKPYVKIMA DSVNIMLDKW EKLDDQDHPL
     EIFHYVSLMT LDTVMKCAFS HQGSVQLDVN SRSYTKAVED LNNLTFFRVR SAFYGNSIIY
     NMSSDGRLSR RACQIAHEHT DGVIKMRKAQ LQNEEELQKA RKKRHLDFLD ILLFAKMEDG
     KSLSDEDLRA EVDTFMFEGH DTTASGISWV FYALATHPEH QERCREEVQS ILGDGTSVTW
     DHLDQIPYTT MCIKEALRLY PPVPSVSREL SSPVTFPDGR SIPKGITTTI LIYGLHHNPS
     YWPNPKVFDP SRFSPDSPRH SHAYLPFSGG ARNCIGKQFA MNELKVAVAL TLLRFELLPD
     PTRIPVPMAR LVLKSKNGIH LRLKKLR
//
